Utah Medical Products Reports Q4 Earnings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 29 2026
0mins
Source: seekingalpha
- Earnings Per Share: Utah Medical Products (UTMD) reported a GAAP EPS of $0.80 for Q4, indicating the company's ability to maintain profitability amidst market challenges.
- Revenue Performance: The revenue for Q4 stood at $9.04 million, reflecting a relatively stable income level despite a projected 5.8% decline in sales for 2025, showcasing the company's market adaptability.
- Gross Profit Analysis: The gross profit for Q4 2025 was $2,142, which is 8.9% lower than in 2024, yet the company successfully limited the dilution of its gross profit margin, demonstrating effective cost control.
- Sales Trends: Despite a 1.2% decline in sales for Q4, gross profit was only $59 (1.1%) lower than Q4 2024, indicating the company's ability to sustain relatively stable profitability even in the face of declining sales.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UTMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UTMD
About UTMD
Utah Medical Products, Inc. develops, manufactures and markets a broad range of disposable and reusable specialty medical devices. The Company has a particular interest in healthcare for women and their babies. The Company’s broad range of products includes those used in critical care areas and the labor and delivery departments of hospitals, as well as outpatient clinics and physicians’ offices. Its products include BT-CATH, CVX-RIPE, AROM-COT, MUC-X, CORDGUARD, DISPOSA-HOOD, DELTRAN PLUS, GESCO, PICC-NATE, LETZ System, Filshie Clip System, PATHFINDER PLUS, SUPRAPUBIC CATHETERIZATION, LIBERTY System, ENDOCURETTE, LUMIN, and BioPharm HP-PRT, among others. BT-CATH is a patented uterine balloon tamponade catheter for controlling severe postpartum hemorrhage. MUC-X is an aspiration device. The Company produces medical devices for blood pressure monitoring and blood management, electrosurgery, labor and delivery, neonatal intensive care, urological care and women’s pelvic health.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Latest Stock Updates from Analyst Blog
- Berkshire Hathaway Performance: Over the past year, Berkshire Hathaway's shares have declined by 2.8%, compared to a 4.3% drop in the insurance sector, indicating challenges in underwriting results due to catastrophic losses, although its strong cash position and diverse operations support financial flexibility.
- Eli Lilly Growth: Eli Lilly's stock has surged by 45.5% in the past year, significantly outperforming the 24% growth in the large-cap pharmaceuticals sector, driven by robust demand for its GLP-1 drugs, while new product launches contribute to substantial revenue growth.
- Walmart's Market Position: Walmart's shares increased by 22.1% over the past year, surpassing the 18.5% growth in the retail supermarket industry, with its scale and expanding omnichannel ecosystem enhancing competitiveness, despite challenges from fuel costs and policy uncertainties.
- Utah Medical Products: Utah Medical Products' shares rose by 27.6% in the past year, reflecting a strong balance sheet with no debt, although a 10.2% revenue decline in Q1 highlights execution risks, yet favorable long-term trends in the medical device sector remain promising.
See More
Utah Medical Products Q1 Financial Results
- Earnings Performance: Utah Medical Products reported a non-GAAP EPS of $0.81 for Q1, maintaining profitability despite facing market challenges.
- Revenue Decline: The company recorded revenues of $8.72 million in Q1, reflecting a 10.2% year-over-year decline, indicating weakened market demand and intensified competition impacting sales.
- Financial Stability: Despite the revenue drop, Utah Medical Products demonstrates a stable financial foundation, continuing to provide returns to shareholders, showcasing resilience in adverse conditions.
- Dividend Performance: The company highlighted strong dividend performance in its report, further bolstering investor confidence in its long-term value, as it remains committed to shareholder returns despite revenue challenges.
See More
Analyst Blog Stock Updates from Zacks
- American Express Outperformance: American Express shares have risen 11.1% over the past year, significantly outperforming the Zacks Financial sector's -17.2%, driven by strong spending growth from Millennials and Gen Z, particularly in travel and dining, enhancing customer engagement and transaction volumes.
- Intuitive Surgical Strong Results: Intuitive Surgical exceeded revenue and EPS estimates in Q4, with 303 placements of the da Vinci 5 system, raising its installed base to 1,232, while global procedures grew 19% year-over-year, indicating robust market demand despite rising costs and budget constraints.
- Shopify's Continued Growth: Shopify shares gained 17.9% over the past year, although below the Internet Services sector's 72.6% growth, as new merchant-friendly tools and AI-driven solutions are helping merchants enhance customer engagement and support international expansion.
- Utah Medical Products Steady Performance: Utah Medical Products' shares rose 13.5% over the past year, with a market cap of $197.44 million and a strong cash position with no debt, providing flexibility for dividends and acquisitions, despite near-term risks from OEM/China exits impacting revenue replacement.
See More
Utah Medical Products Reports Q4 Earnings
- Earnings Per Share: Utah Medical Products (UTMD) reported a GAAP EPS of $0.80 for Q4, indicating the company's ability to maintain profitability amidst market challenges.
- Revenue Performance: The revenue for Q4 stood at $9.04 million, reflecting a relatively stable income level despite a projected 5.8% decline in sales for 2025, showcasing the company's market adaptability.
- Gross Profit Analysis: The gross profit for Q4 2025 was $2,142, which is 8.9% lower than in 2024, yet the company successfully limited the dilution of its gross profit margin, demonstrating effective cost control.
- Sales Trends: Despite a 1.2% decline in sales for Q4, gross profit was only $59 (1.1%) lower than Q4 2024, indicating the company's ability to sustain relatively stable profitability even in the face of declining sales.
See More
UTMD Reports Year-over-Year Decline in Q3 Earnings Due to Trade Disruptions and Margin Pressures
Stock Performance: Utah Medical Products, Inc. (UTMD) shares have declined 4.1% following a disappointing earnings report for Q3 2025, contrasting with a 2.8% growth in the S&P 500 during the same period.
Earnings and Revenue Decline: The company reported a 19.9% drop in earnings per share (EPS) to 82 cents and a 1.9% decrease in revenue to $9.8 million, attributed to trade disruptions and a weaker sales pipeline.
Operational Challenges: Significant factors impacting performance included unexpected order cancellations from non-U.S. distributors, increased manufacturing costs due to tariffs, and reduced sales from a former major customer, PendoTECH.
Future Outlook: Management revised full-year 2025 revenue expectations to a 7% decline, reflecting ongoing economic challenges, while also highlighting strong cash generation capabilities through share repurchases and dividends.
See More
UTMD's Q2 Earnings Slip Y/Y Due to Falling OEM Sales, Stock Down 3%
Earnings Report Overview: Utah Medical Products, Inc. (UTMD) reported a 4% decline in earnings per share and a 4.3% decrease in net sales for Q2 2025 compared to the previous year, with domestic sales slightly increasing while international sales dropped significantly.
Future Outlook: Management anticipates continued weakness in PendoTECH sales affecting full-year results, but remains optimistic about achieving a trailing twelve-month EBITDA target of $16 million to $18 million despite current challenges.
See More
Latest Stock Updates from Analyst Blog
- Berkshire Hathaway Performance: Over the past year, Berkshire Hathaway's shares have declined by 2.8%, compared to a 4.3% drop in the insurance sector, indicating challenges in underwriting results due to catastrophic losses, although its strong cash position and diverse operations support financial flexibility.
- Eli Lilly Growth: Eli Lilly's stock has surged by 45.5% in the past year, significantly outperforming the 24% growth in the large-cap pharmaceuticals sector, driven by robust demand for its GLP-1 drugs, while new product launches contribute to substantial revenue growth.
- Walmart's Market Position: Walmart's shares increased by 22.1% over the past year, surpassing the 18.5% growth in the retail supermarket industry, with its scale and expanding omnichannel ecosystem enhancing competitiveness, despite challenges from fuel costs and policy uncertainties.
- Utah Medical Products: Utah Medical Products' shares rose by 27.6% in the past year, reflecting a strong balance sheet with no debt, although a 10.2% revenue decline in Q1 highlights execution risks, yet favorable long-term trends in the medical device sector remain promising.
See More
Utah Medical Products Q1 Financial Results
- Earnings Performance: Utah Medical Products reported a non-GAAP EPS of $0.81 for Q1, maintaining profitability despite facing market challenges.
- Revenue Decline: The company recorded revenues of $8.72 million in Q1, reflecting a 10.2% year-over-year decline, indicating weakened market demand and intensified competition impacting sales.
- Financial Stability: Despite the revenue drop, Utah Medical Products demonstrates a stable financial foundation, continuing to provide returns to shareholders, showcasing resilience in adverse conditions.
- Dividend Performance: The company highlighted strong dividend performance in its report, further bolstering investor confidence in its long-term value, as it remains committed to shareholder returns despite revenue challenges.
See More
Analyst Blog Stock Updates from Zacks
- American Express Outperformance: American Express shares have risen 11.1% over the past year, significantly outperforming the Zacks Financial sector's -17.2%, driven by strong spending growth from Millennials and Gen Z, particularly in travel and dining, enhancing customer engagement and transaction volumes.
- Intuitive Surgical Strong Results: Intuitive Surgical exceeded revenue and EPS estimates in Q4, with 303 placements of the da Vinci 5 system, raising its installed base to 1,232, while global procedures grew 19% year-over-year, indicating robust market demand despite rising costs and budget constraints.
- Shopify's Continued Growth: Shopify shares gained 17.9% over the past year, although below the Internet Services sector's 72.6% growth, as new merchant-friendly tools and AI-driven solutions are helping merchants enhance customer engagement and support international expansion.
- Utah Medical Products Steady Performance: Utah Medical Products' shares rose 13.5% over the past year, with a market cap of $197.44 million and a strong cash position with no debt, providing flexibility for dividends and acquisitions, despite near-term risks from OEM/China exits impacting revenue replacement.
See More
Utah Medical Products Reports Q4 Earnings
- Earnings Per Share: Utah Medical Products (UTMD) reported a GAAP EPS of $0.80 for Q4, indicating the company's ability to maintain profitability amidst market challenges.
- Revenue Performance: The revenue for Q4 stood at $9.04 million, reflecting a relatively stable income level despite a projected 5.8% decline in sales for 2025, showcasing the company's market adaptability.
- Gross Profit Analysis: The gross profit for Q4 2025 was $2,142, which is 8.9% lower than in 2024, yet the company successfully limited the dilution of its gross profit margin, demonstrating effective cost control.
- Sales Trends: Despite a 1.2% decline in sales for Q4, gross profit was only $59 (1.1%) lower than Q4 2024, indicating the company's ability to sustain relatively stable profitability even in the face of declining sales.
See More
UTMD Reports Year-over-Year Decline in Q3 Earnings Due to Trade Disruptions and Margin Pressures
Stock Performance: Utah Medical Products, Inc. (UTMD) shares have declined 4.1% following a disappointing earnings report for Q3 2025, contrasting with a 2.8% growth in the S&P 500 during the same period.
Earnings and Revenue Decline: The company reported a 19.9% drop in earnings per share (EPS) to 82 cents and a 1.9% decrease in revenue to $9.8 million, attributed to trade disruptions and a weaker sales pipeline.
Operational Challenges: Significant factors impacting performance included unexpected order cancellations from non-U.S. distributors, increased manufacturing costs due to tariffs, and reduced sales from a former major customer, PendoTECH.
Future Outlook: Management revised full-year 2025 revenue expectations to a 7% decline, reflecting ongoing economic challenges, while also highlighting strong cash generation capabilities through share repurchases and dividends.
See More
UTMD's Q2 Earnings Slip Y/Y Due to Falling OEM Sales, Stock Down 3%
Earnings Report Overview: Utah Medical Products, Inc. (UTMD) reported a 4% decline in earnings per share and a 4.3% decrease in net sales for Q2 2025 compared to the previous year, with domestic sales slightly increasing while international sales dropped significantly.
Future Outlook: Management anticipates continued weakness in PendoTECH sales affecting full-year results, but remains optimistic about achieving a trailing twelve-month EBITDA target of $16 million to $18 million despite current challenges.
See More
